BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 24048162)

  • 1. Lubiprostone for the treatment of functional constipation in children.
    Hyman PE; Di Lorenzo C; Prestridge LL; Youssef NN; Ueno R
    J Pediatr Gastroenterol Nutr; 2014 Mar; 58(3):283-91. PubMed ID: 24048162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lubiprostone: chloride channel activator for chronic constipation.
    Rivkin A; Chagan L
    Clin Ther; 2006 Dec; 28(12):2008-21. PubMed ID: 17296458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation.
    Johanson JF; Morton D; Geenen J; Ueno R
    Am J Gastroenterol; 2008 Jan; 103(1):170-7. PubMed ID: 17916109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, placebo-controlled trial of lubiprostone for opioid-induced constipation in chronic noncancer pain.
    Jamal MM; Adams AB; Jansen JP; Webster LR
    Am J Gastroenterol; 2015 May; 110(5):725-32. PubMed ID: 25916220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of lubiprostone in patients with chronic constipation.
    Barish CF; Drossman D; Johanson JF; Ueno R
    Dig Dis Sci; 2010 Apr; 55(4):1090-7. PubMed ID: 20012484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety.
    Johanson JF; Ueno R
    Aliment Pharmacol Ther; 2007 Jun; 25(11):1351-61. PubMed ID: 17509103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation.
    Chey WD; Drossman DA; Johanson JF; Scott C; Panas RM; Ueno R
    Aliment Pharmacol Ther; 2012 Mar; 35(5):587-99. PubMed ID: 22251419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lubiprostone in pediatric functional constipation.
    Faure C
    J Pediatr Gastroenterol Nutr; 2014 Mar; 58(3):275-7. PubMed ID: 24345830
    [No Abstract]   [Full Text] [Related]  

  • 9. Lubiprostone for constipation in adults with cystic fibrosis: a pilot study.
    O'Brien CE; Anderson PJ; Stowe CD
    Ann Pharmacother; 2011 Sep; 45(9):1061-6. PubMed ID: 21852592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lubiprostone increases spontaneous bowel movement frequency and quality of life in patients with chronic idiopathic constipation.
    Fukudo S; Hongo M; Kaneko H; Takano M; Ueno R
    Clin Gastroenterol Hepatol; 2015 Feb; 13(2):294-301.e5. PubMed ID: 25158925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized study of lubiprostone for opioid-induced constipation in patients with chronic noncancer pain.
    Cryer B; Katz S; Vallejo R; Popescu A; Ueno R
    Pain Med; 2014 Nov; 15(11):1825-34. PubMed ID: 24716835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lubiprostone vs Senna in postoperative orthopedic surgery patients with opioid-induced constipation: a double-blind, active-comparator trial.
    Marciniak CM; Toledo S; Lee J; Jesselson M; Bateman J; Grover B; Tierny J
    World J Gastroenterol; 2014 Nov; 20(43):16323-33. PubMed ID: 25473191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lubiprostone: a chloride channel activator for treatment of chronic constipation.
    Ambizas EM; Ginzburg R
    Ann Pharmacother; 2007 Jun; 41(6):957-64. PubMed ID: 17519292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome.
    Chamberlain SM; Rao SS
    Expert Opin Drug Saf; 2012 Sep; 11(5):841-50. PubMed ID: 22834474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lubiprostone.
    McKeage K; Plosker GL; Siddiqui MA
    Drugs; 2006; 66(6):873-9. PubMed ID: 16706562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lubiprostone for Pediatric Functional Constipation: Randomized, Controlled, Double-Blind Study With Long-term Extension.
    Benninga MA; Hussain SZ; Sood MR; Nurko S; Hyman P; Clifford RA; O'Gorman M; Losch-Beridon T; Mareya S; Lichtlen P; Di Lorenzo C
    Clin Gastroenterol Hepatol; 2022 Mar; 20(3):602-610.e5. PubMed ID: 33838349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lubiprostone for chronic idiopathic constipation and irritable bowel syndrome with constipation.
    Saad R; Chey WD
    Expert Rev Gastroenterol Hepatol; 2008 Aug; 2(4):497-508. PubMed ID: 19072397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lubiprostone for constipation and irritable bowel syndrome with constipation.
    Tuteja AK; Rao SS
    Expert Rev Gastroenterol Hepatol; 2008 Dec; 2(6):727-33. PubMed ID: 19090733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term safety and effectiveness of lubiprostone, a chloride channel (ClC-2) activator, in patients with chronic idiopathic constipation.
    Lembo AJ; Johanson JF; Parkman HP; Rao SS; Miner PB; Ueno R
    Dig Dis Sci; 2011 Sep; 56(9):2639-45. PubMed ID: 21769655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation.
    Johanson JF; Drossman DA; Panas R; Wahle A; Ueno R
    Aliment Pharmacol Ther; 2008 Apr; 27(8):685-96. PubMed ID: 18248656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.